San Diego-based Traversa Therapeutics today announced it has raised $5 million in a Series B financing round; Morningside Venture Investments led the deal, which was joined by Mesa Verde Venture Partners and existing investors. The company says the money will help it move its RNAi-based treatments for cancer into clinical trials. Founded in mid-2006, Traversa previously raised $2 million in a round led by San Diego Tech Coast Angels.